Latest Conference Articles

The treatment recently became the first ever FDA-approved medication for EoE.

With administration strategies for the psychiatric anesthetic drug well established, clinicians have interest in accumulating long-term data and other potential indications.

Brent Forester, MD, MSc, discusses the confluence of biomarker and disease-targeting therapy in Alzheimer's, and the need to appropriately introduce these tools.

The director of NIDA discusses the unprecedented impact of the pandemic on overdose deaths—and how substance use disorder care may still reach greater capability when all is said and done.

Dementia and Alzheimer's disease cases are anticipated to boom in coming decades. One expert stressed the need for improved screening and facilitation of care at the earliest stages and signs.

Data show the proportion of individuals with sustained clinical cure through Week 8 was 80.3% with CP101 treatment.

The lead author of treatment recommendations weighs in on their current use and future research.

Initial studies have shown a 73% efficacy for FMT in treating patients with HVGD.

BMI did not have an association with increased risk for death in any BMI category, according to study investigators.

A look into the efficacy of ozanimod in patients with UC and the potential risk for cardiovascular events.

The live microbiota therapeutic has shown promise in treating patients with recurrent CDI.

Patients who have IPAA are more than twice as likely to suffer from male sexual dysfunction.

Patients treated with TNF- antagonists had a higher deep remission rate compared to patients treated with ustekinumab.

Patients with IBD are often at an increased risk of developing NAFLD.

New data from DDW 2022 show inpatient mortality rates were lower in patients with history of bariatric surgery.

Dr. Blount discusses the DDW 2022 poster of distinction on the investigational live biotherapeutic.

Amid significant psychotherapy innovation and consideration to broader aspects of mental illness definition, Jonathan Alpert, MD, PhD, emphasizes the need for improved clinical trial standards.

Post-treatment, data show molecular age remained significantly greater than chronological age at a median difference of 18.6 years.

New phase 3 data presented at APA 2022 support the agent as an adjunctive in older patients without benefit from monotherapy antidepressant medication.

The data presented at DDW show similar safety and efficacy for the 2 treatments.

Montefiore psychiatry chair Jonathan Alpert, MD, PhD, discusses suggested updates to the DSM-5—with consideration to social determinants and patient-reported functioning.

Recurrence commonly occurred during the first 2 weeks regardless of treatment.

Linda Chokroverty, MD, discusses the significance of timing, communication and care coordination when children are affected by disasters or trauma.

APA president-elect Rebecca W. Brendel, MD, JD, discusses the need to prepare for a "twin mental health pandemic" while continuing to appropriately facilitate innovations in psychiatric care.

Anita Clayton, MD, reviews the available phase 2 and 3 clinical data for the novel, once-daily oral investigative drug.

Linda Chokroverty, MD, discusses the role psychiatrists play in managing the mental health effects of disasters, and how children specifically may be impacted.

Both post-transplant PPI and histamine-2 receptor antagonist use were independently associated with reduced risk of 1-year mortality.

A pair of psychiatrists discuss how climate change and other social determinants of health are affecting the mental wellbeing of indigenous people.

DASH diet was inversely associated with NAFLD risk, independent of BMI changes.

The treatment did not improve sustained virologic response but did increase the rate of treatment-related adverse events.